FOLLOW US

For nearly a year, the top office at the Centers for Disease Control and Prevention sat like a captain's chair on a ship without a captain — steered instead by a rotating cast of temporary hands. That changed Wednesday, when the Senate confirmed Dr. Erica Schwartz as the agency's permanent director, closing a chapter marked by political turbulence and plummeting morale.

The Erica Schwartz CDC director confirmation passed by a 51-44 vote, making the 54-year-old the 22nd person to lead the Atlanta-based agency and, notably, its first Senate-confirmed director in nearly a year.

A Résumé Built for the Moment

Credentials That Turned Heads

Schwartz arrives with a background that reads like a checklist for the job: medical and law degrees, a previous stint as deputy surgeon general, and leadership experience within the U.S. Coast Guard. It's the kind of résumé that suggests someone equally comfortable navigating scientific data and bureaucratic minefields — a dual skill set the CDC desperately needs after a turbulent stretch.

A Rocky Start to the Confirmation Process

Schwartz's path to confirmation wasn't smooth sailing from the start. During a hearing before the Senate Health, Education, Labor and Pensions Committee last month, her nomination wobbled under pointed questioning. Committee Chairman Sen. Bill Cassidy, R-La., along with several colleagues, pressed her on whether she'd be willing to push back against Health Secretary Robert F. Kennedy Jr. if he pushed the CDC toward decisions unsupported by science.

But the tide turned in the weeks that followed. Cassidy later said he'd spoken directly with Schwartz, along with others familiar with her work, and emerged with newfound confidence in her ability to lead — a reversal that ultimately cleared the path for her confirmation.

An Agency in Crisis

The Numbers Tell a Sobering Story

The CDC hasn't just experienced turbulence since Trump returned to office last year — it's weathered something closer to an institutional earthquake. Layoffs and resignations have stripped the agency of more than 3,000 employees, over a quarter of its entire workforce. Morale has cratered as a revolving door of mostly temporary leaders has cycled through the top office, while political appointees with little or no medical or public health training have staffed key positions in the front office.

Cautious Optimism From the Public Health Community

When Schwartz was nominated back in April, public health experts greeted the news with tempered hope, pointing to her qualifications as a genuine bright spot. They also noted something politically significant: Schwartz was Trump's pick, not Kennedy's — a distinction that mattered given Kennedy's history as a prominent voice in the anti-vaccine movement before he took charge of the CDC and other federal health agencies.

Third Time's the Charm

A Nomination That Collapsed Before It Began

Schwartz becomes the third person Trump has nominated for CDC director in just 18 months — a revolving door that has tested the agency's stability like a building shaken by repeated aftershocks. The first nominee, former Florida Congressman Dr. David Weldon, saw his Senate hearing canceled just an hour before it was set to begin in March 2025. Weldon said at the time he'd been told there simply weren't enough votes to confirm him.

A Confirmed Director Ousted Within Weeks

The White House then turned to Susan Monarez, who had been serving as the CDC's acting director. Monarez cleared Senate confirmation — only to be pushed out of the job in less than a month. Trump administration officials said she wasn't sufficiently aligned with the president's agenda, and she was subsequently terminated, leaving the agency once again without steady leadership.

A Revolving Door of Acting Leaders

In the aftermath, a succession of Health and Human Services officials cycled through the role of acting CDC director, none staying long enough to provide the kind of stability the agency badly needed.

A Broader Leadership Vacuum

The CDC's leadership gap hasn't existed in isolation. It's been one piece of a larger puzzle of vacancies across federal health agencies, including the U.S. surgeon general and the commissioner of the Food and Drug Administration — vacancies that have left multiple pillars of the nation's public health infrastructure without permanent leadership at a critical moment.

What Comes Next for the CDC

With Schwartz now confirmed, the agency faces the daunting task of rebuilding morale, restoring staffing levels, and re-establishing public trust after a year defined by upheaval. Whether her leadership can steady the ship — and whether she'll maintain the independence lawmakers hope for — remains a question only time, and future policy decisions, will answer.